Sodium-dependent phosphate transport protein 2B (NaPi2b) is a protein that in humans is encoded by the SLC34A2 gene.
Sodium-dependent phosphate transport protein 2b (NaPi2b) is a tumor-associated antigen.
As of April 2023, upifitamab rilsodotin, an antibody-drug conjugate (ADC) targeting NaPi2b, is in Phase 3 clinical trials for recurrent platinum-sensitive ovarian cancer.